Last month, the Dutch Ministry of Health, Welfare and Sport (VWS) announced that it will not include the breast cancer drug Trodelvy (sacituzumab govitecan-hziy) in the country’s standard package of pharmacy and medical benefits.
Subscribe to:
Post Comments (Atom)
< + > Real-Time Pharma Insights: Philip Poulidis on Scaling ODAIA AI – Life Sciences Today Podcast Episode 41
We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Philip Poulidis, ...
No comments:
Post a Comment